aap: Fame Medical Group Takeover Completed Successfully
The capital increase by a contribution in kind agreed at the extraordinary general meeting of aap Implantate AG held on February 15, 2007 was today entered into the commercial register. Lawsuits filed by individual shareholders had delayed the entry. aap thereupon embarked on fast track proceedings, an option available since 2006 that is intended to enhance the legal and procedural security of companies affected by lawsuits filed in connection with shareholders’ meetings.
The register entry increases aap Implantate AG’s capital stock by EUR 8,448,999.00 to EUR 25,347,156.00, divided into 25,347,156 individual share certificates. Listing of the new shares for stock market trading is planned for the weeks ahead. Due to contractual provisions 50 percent of the new shares are subject to a 12month lockup period after listing.
aap Implantate AG
aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotical carriers, implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003.